Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lungcancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lungcancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung (...) 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly
Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell LungCancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
LungCancer Screening New 2018 ACR Appropriateness Criteria ® 1 LungCancer Screening American College of Radiology ACR Appropriateness Criteria ® LungCancer Screening Variant 1: Lungcancer screening. Patient 55 to 80 years of age and 30 or more packs per year smoking history and currently smoke or have quit within the past 15 years. Procedure Appropriateness Category Relative Radiation Level CT chest without IV contrast screening Usually Appropriate ??? CT chest with IV contrast Usually (...) Not Appropriate ??? CT chest without and with IV contrast Usually Not Appropriate ??? FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O Radiography chest Usually Not Appropriate ? Variant 2: Lungcancer screening. Patient 50 years of age or older and 20 or more packs per year history of smoking and one additional risk factor (ie, radon exposure or occupational exposure
Smoking and LungCancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer.To project reductions in tobacco use and lungcancer mortality from 2015 to 2065 due to existing tobacco control efforts.Comparative modeling approach using 4 simulation models of the natural history of lungcancer (...) that explicitly relate temporal smoking patterns to lungcancer rates.U.S. population, 1964 to 2065.Adults aged 30 to 84 years.Models were developed using U.S. data on smoking (1964 to 2015) and lungcancer mortality (1969 to 2010). Each model projected lungcancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios.Under the assumption of continued decreases
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lungcancer (NSCLC): a review of the literature Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lungcancer (NSCLC). Tobacco smoking is the number one risk factor for lungcancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed (...) to review the knowledge in immunotherapy.A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lungcancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two
Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell LungCancer: A Multiinstitutional Study There is currently no consensus regarding the optimal postoperative follow-up strategy for patients with completely resected non-small cell lungcancer (NSCLC). We aimed to develop web-based nomograms to precisely predict site-specific postoperative recurrence in patients with NSCLC (...) and to guide individual surveillance strategies including when to follow up and what diagnostic tests to perform.We investigated the pattern of recurrence in a series of 2,017 patients with NSCLC (squamous cell carcinoma and nonlepidic invasive adenocarcinoma) who underwent complete surgical resection at Fudan University Shanghai Cancer Center (development cohort), and developed web-based clinicopathologic prediction models for conditional risk of site-specific recurrence based on Cox regression
ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell LungCancer Special Article Palliative thoracic radiation therapy for non- small cell lungcancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation (...) Oncology Center, Turlock, California h Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lungcancer. Methods
Gefitinib Mylan - non-small cell lungcancer Gefitinib Mylan | European Medicines Agency Search Search Menu Gefitinib Mylan gefitinib Table of contents Authorised This medicine is authorised for use in the European Union. Overview Gefitinib Mylan is a cancer medicine used to treat adults who have non-small cell lungcancer that is locally advanced or metastatic (when cancer cells have spread from the original site to other parts of the body). It is used in patients whose cancer cells have (...) on the surface of cancer cells, such as EGFR on the surface of non-small cell lungcancer cells. EGFR is involved in the growth and spread of cancer cells. By blocking EGFR, Gefitinib Mylan helps to slow down the growth and spread of the cancer. Gefitinib Mylan works only in non-small cell lungcancer cells that have a mutation in their EGFR. How has Gefitinib Mylan been studied? Studies on the benefits and risks of the in the authorised use have already been carried out with the reference medicine, Iressa
Treating EGFR-Mutated Oncogene-Addicted Advanced Nonâ€“Small-Cell LungCancer in the Era of Economic Crisis in Greece: Challenges and Opportunities Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR (...) ) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lungcancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis.From 2011 through 2015, 252 patients with newly diagnosed advanced NSCLC were treated at the Department of Medical Oncology of the Papageorgiou Hospital, a tertiary cancer center in northern Greece. We
Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lungcancer and their family caregivers. Compared to cancers at other sites, lungcancer often results in greater psychosocial distress to both the patients and their caregivers, due to the poor prognosis and survival rate, as well as the heavy symptom burden. In recent years, making protocols of proposed or on-going (...) intervention with cognitive behavioral therapy for enhancing quality of life of patients with lungcancer and their family caregivers. The data collection process was still on-going at the time of manuscript submission.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell LungCancer. Standard first-line therapy for metastatic, squamous non-small-cell lungcancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.In this double-blind, phase 3 trial, we randomly assigned
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell LungCancer. Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lungcancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus (...) carboplatin and etoposide in patients with extensive-stage small-cell lungcancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell LungCancer. Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lungcancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear.In an open-label, phase 3 trial, we randomly assigned, in a 1:1 ratio
Comparable immunoreactivity rates of PDâ€L1 in archival and recent specimens from nonâ€small cell lungcancer Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling (...) /paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lungcancer (NSCLC).This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies.There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28-8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28-8 antibodies was observed. The immunoreactivity rate achieved